Cordis Medical Device Company Intelligence Report

Summary

Based in Miami Lakes, Florida, USA, Johnson & Johnson's Cordis unit manufactures and markets products for interventional medicine, minimally-invasive computer-based imaging and electrophysiology (EP). The company's products are marketed through four divisions: Cordis Cardiology for coronary applications, Cordis Endovascular for vascular disease, Biosense Webster for EP in cardiovascular procedures and Cordis Neurovascular which leverages the company's technology into applications for the brain, as follows:-

Cordis Cardiology, based at the Cordis headquarters in Miami Lakes, is the company's largest business and manufactures diagnostic, interventional products and stents. Cordis Cardiology claims to have created the diagnostic market and introduced nylon balloon technology.

Cordis Neurovascular was formed in 1993 in order to leverage technologies used in cardiology and peripheral systems into the brain. In 1994, the division claimed to have introduced the first neurointerventional microcatheter which utilised braided technology and expanded the treatment opportunities for cerebrovascular disease.

Cordis Endovascular, based in Warren, New Jersey, USA, manufactures interventional and diagnostic medical products, including nitinol and stainless steel stents, carotid stenting products, vena cava filters, balloon catheters and accessories. The company serves the cardiology, radiology and vascular surgery communities with technologies for treating peripheral vascular disease.

Biosense Webster, based in Diamond Bar, California, USA, is a leader in intracardiac EP and interventional cardiology, having pioneered the development of 3D cardiac mapping and navigation for disease evaluation and therapy.

In addition, Cordis' Biologics Delivery Systems unit develops and markets technology for cardiac navigation and mapping across multiple disease states and clinical specialties. Its initial focus is on providing technology to advance the treatment of cardiovascular and vascular disease such as congestive heart failure, the leading cause of death in the US, and chronic ischaemia.

Currently, Cordis operates US sites in Warren and Raritan, New Jersey, for endovascular products and in Miami Lakes, Florida, for cardiology and neurovascular products. Its Nitinol Devices and Components and LuMend units are based in California. Internationally, Cordis has operations in Mexico, Puerto Rico, the Netherlands, Belgium, Italy, Germany and France. It is also building a facility in Cashel, Ireland, and an R&D centre in Silicon Valley, California, USA. Biosense Webster has US manufacturing sites in Baldwin Park and Irwindale, California, and international operations in Israel and Mexico.

Cordis received an FDA Warning Letter in 2004 regarding Good Manufacturing Practice and Good Clinical Practice regulations following post-approval site inspections at its facilities in Miami Lakes, Florida, and Warren, New Jersey, USA; San German, Puerto Rico; Roden, the Netherlands; Beerse, Belgium; and Latina, Italy. In June 2007, Cordis received notification from the FDA that all items outlined in the Warning Letters had been resolved.

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Content